Johnson & Johnson Enters New Era in Solid Tumors at ESMO 2025 With Promising Data Across Multiple Cancer Types
October 16, 2025
October 16, 2025
RARITAN, New Jersey, Oct. 16 (TNSxrep) -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release on Oct. 15, 2025:
* * *
Johnson & Johnson enters new era in solid tumors at ESMO 2025 with promising data across multiple cancer types
First report of subcutaneous amivantamab demonstrates compelling clinical activity in recurrent or metastatic head and neck cancer, bui . . .
* * *
Johnson & Johnson enters new era in solid tumors at ESMO 2025 with promising data across multiple cancer types
First report of subcutaneous amivantamab demonstrates compelling clinical activity in recurrent or metastatic head and neck cancer, bui . . .